BG106507A - AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES - Google Patents

AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES

Info

Publication number: BG106507A
Authority: BG; Bulgaria
Prior art keywords: pyrazolo; disorders; compounds; pyramidines; triazines
Prior art date: 1999-09-30

Application number

BG106507A

Other languages

Bulgarian (bg)

English (en)

Inventor

James DARROW

Lombaert Stephane De

Charles Blum

Jennifer Tran

Mark Giangiordano

David Griffith

Philip Carpino

Original Assignee

Neurogen Corporation

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-30

Filing date

2002-03-11

Publication date

2002-12-29

2002-03-11 Application filed by Neurogen Corporation, Pfizer Inc. filed Critical Neurogen Corporation

2002-12-29 Publication of BG106507A publication Critical patent/BG106507A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5755—Neuropeptide Y
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG106507A 1999-09-30 2002-03-11 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES BG106507A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15686899P	1999-09-30	1999-09-30
PCT/US2000/026885 WO2001023388A2 (fr)	1999-09-30	2000-09-29	Pyrazolo[1,5,-a]-1,5-pyrimidines et pyrazolo[1,5-a]-1,3,5-triazines amino substituees

Publications (1)

Publication Number	Publication Date
BG106507A true BG106507A (en)	2002-12-29

Family

ID=22561433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106507A BG106507A (en)	1999-09-30	2002-03-11	AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES

Country Status (21)

Country	Link
US (1)	US6476038B1 (fr)
EP (1)	EP1218381B1 (fr)
JP (2)	JP2003510326A (fr)
KR (1)	KR20020047201A (fr)
CN (1)	CN1377355A (fr)
AT (1)	ATE347553T1 (fr)
AU (1)	AU7737900A (fr)
BG (1)	BG106507A (fr)
CA (1)	CA2379633C (fr)
CZ (1)	CZ20021089A3 (fr)
DE (1)	DE60032249T2 (fr)
EA (1)	EA200200421A1 (fr)
ES (1)	ES2277855T3 (fr)
HU (1)	HUP0203131A3 (fr)
IL (1)	IL148904A0 (fr)
NO (1)	NO20021357L (fr)
OA (1)	OA12049A (fr)
PL (1)	PL354982A1 (fr)
WO (1)	WO2001023388A2 (fr)
YU (1)	YU23602A (fr)
ZA (1)	ZA200202517B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6472528B1 (en) *	1999-08-10	2002-10-29	Neurocrine Biosciences, Inc.	Synthesis of substituted pyrazolopyrimidines
WO2001023387A2 (fr) *	1999-09-30	2001-04-05	Neurogen Corporation	PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES A SUBSTITUTION ALKYLENE-DIAMINE ET PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
AU2003217712A1 (en)	2002-03-07	2003-09-22	Smithkline Beecham Corporation	Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
FR2842809A1 (fr) *	2002-07-26	2004-01-30	Greenpharma Sas	NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2295816T3 (es)	2003-01-14	2008-04-16	Arena Pharmaceuticals, Inc.	Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) *	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) *	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
EA008596B1 (ru)	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en)	2003-07-14	2006-11-07	Arena Pharmaceuticals, Inc.	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
ATE547404T1 (de)	2003-09-22	2012-03-15	Msd Kk	Piperidinderivate
US7208596B2 (en)	2003-11-25	2007-04-24	Bristol-Myers Squibb Pharma Company	Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2 (en)	2003-11-25	2006-12-26	Bristol-Myers Squibb Pharma Co.	Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US7737154B2 (en)	2003-12-22	2010-06-15	Smithkline Beecham (Cork) Limited	CRF receptor antagonists and methods relating thereto
WO2005063756A1 (fr) *	2003-12-22	2005-07-14	Sb Pharmco Puerto Rico Inc	Antagonistes du recepteur de crf et procedes correspondants
EP1734963A4 (fr)	2004-04-02	2008-06-18	Merck & Co Inc	Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
GB0519957D0 (en) *	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
EP2286837A3 (fr)	2004-11-01	2013-09-04	Amylin Pharmaceuticals, LLC	Traitement de l'obésité et de maladies liés à l'obésité
ES2327145T3 (es) *	2004-12-21	2009-10-26	Schering Corporation	Anatagonistas del receptor de adenosina a2a de pirazolo(1,5-a)pirimidina sustituidos.
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en)	2005-05-30	2011-03-31	Banyu Pharma Co Ltd	Piperidine derivatives as histamine-H3 receptor antagonists
CA2836319A1 (fr)	2005-06-23	2006-12-28	Statens Serum Institut	Ameliorations apportees a des vaccins contre la tuberculose
US20100216758A1 (en)	2005-08-10	2010-08-26	Makoto Ando	Pyridone Compounds
AU2006279680B2 (en)	2005-08-11	2012-12-06	Amylin Pharmaceuticals, Llc	Hybrid polypeptides with selectable properties
EP2330125A3 (fr)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Polypeptides hybrides ayant des propriétés sélectionnables
AU2006282260A1 (en)	2005-08-24	2007-03-01	Msd K.K.	Phenylpyridone derivative
EP1939194A4 (fr)	2005-09-07	2010-12-08	Banyu Pharma Co Ltd	Dérivé de pyridone substitué aromatique bicylique
CN101277960A (zh)	2005-09-29	2008-10-01	默克公司	作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
WO2007048027A2 (fr)	2005-10-21	2007-04-26	Novartis Ag	Combinaison de composes organiques
CA2627139A1 (fr)	2005-10-27	2007-05-03	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de benzoxathiine
WO2007055418A1 (fr)	2005-11-10	2007-05-18	Banyu Pharmaceutical Co., Ltd.	Derive spiro aza-substitue
CN101516886B (zh) *	2006-09-20	2012-02-29	伊莱利利公司	噻吩吡唑并嘧啶化合物
EP2094709B1 (fr) *	2006-09-20	2010-09-15	Eli Lilly And Company	Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1
EP2698157B1 (fr)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
WO2008151257A2 (fr)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2155725A1 (fr) *	2007-06-07	2010-02-24	Schering Corporation	Synthèse d'aminopyrazoles substitués en position 3
JPWO2009110510A1 (ja)	2008-03-06	2011-07-14	Ｍｓｄ株式会社	アルキルアミノピリジン誘導体
US20110015198A1 (en)	2008-03-28	2011-01-20	Banyu Pharmaceutical Co., Inc.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
WO2009149279A2 (fr)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
CA2727914A1 (fr)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Derive de spirodiamine-diarylcetoxime
US20100015171A1 (en)	2008-07-15	2010-01-21	Statens Serum Institute	Vaccines comprising tb 10.4
CA2730603C (fr)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase utiles dans le traitement des affections gastro-intestinales, de l'inflammation gastro-intestinale, du cancer gastro-intestinal et d'autres affections
EP2319841A1 (fr)	2008-07-30	2011-05-11	Msd K.K.	Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons) (6 chaînons)
CA2741125A1 (fr)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques
AU2009308980B2 (en)	2008-10-30	2013-02-28	Merck Sharp & Dohme Corp.	Isonicotinamide orexin receptor antagonists
WO2010051206A1 (fr)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (fr)	2008-12-16	2010-07-01	Schering Corporation	Dérivés de pyridopyrimidine et leurs procédés d'utilisation
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP2619198A1 (fr)	2010-09-22	2013-07-31	Arena Pharmaceuticals, Inc.	Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés
BR112013021236B1 (pt)	2011-02-25	2021-05-25	Merck Sharp & Dohme Corp	composto derivado de benzimidazol, e, composição
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9527875B2 (en)	2012-08-02	2016-12-27	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
NZ707432A (en) *	2012-11-16	2020-01-31	Univ Health Network	Pyrazolopyrimidine compounds
MX2015010935A (es)	2013-02-22	2015-10-29	Merck Sharp & Dohme	Compuestos biciclicos antidiabeticos.
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2970384A1 (fr)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et leurs utilisations
AU2014274812B2 (en)	2013-06-05	2018-09-27	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Composés tricycliques antidiabétiques
DK3186242T3 (da)	2014-08-29	2021-12-20	Tes Pharma S R L	Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR102411150B1 (ko)	2016-08-31	2022-06-21	아지오스 파마슈티컬스 아이엔씨.	세포 대사 과정의 억제제
AR109950A1 (es)	2016-10-14	2019-02-06	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3551176A4 (fr)	2016-12-06	2020-06-24	Merck Sharp & Dohme Corp.	Composés hétérocycliques antidiabétiques
WO2018118670A1 (fr)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Composés de spirochromane antidiabétiques
AU2018220521A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
US20210361664A1 (en)	2017-08-14	2021-11-25	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
US11691938B2 (en) *	2018-04-10	2023-07-04	Bayer Aktiengesellschaft	Process for preparing 2,6-dialkylphenylacetic acids
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
MY210039A (en)	2018-10-30	2025-08-22	Kronos Bio Inc	Compounds, compositions, and methods for modulating cdk9 activity
BR112021009589A2 (pt)	2018-11-20	2021-08-17	Tes Pharma S.R.L.	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US12331018B2 (en)	2019-02-13	2025-06-17	Merck Sharp & Dohme Llc	Pyrrolidine orexin receptor agonists
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (fr)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
MX2023001688A (es)	2020-08-12	2023-02-22	Spruce Biosciences Inc	Metodos y composiciones para tratar el sindrome de ovario poliquistico.
MX2023001840A (es)	2020-08-18	2023-03-13	Merck Sharp & Dohme Llc	Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
CN115304607B (zh) *	2022-07-06	2023-06-27	华南农业大学	吡唑并嘧啶衍生物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU229024B1 (en) *	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
ID24300A (id) *	1997-08-05	2000-07-13	Pfizer Prod Inc	4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
US6187777B1 (en) *	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases

2000
- 2000-09-29 KR KR1020027004178A patent/KR20020047201A/ko not_active Ceased
- 2000-09-29 CA CA002379633A patent/CA2379633C/fr not_active Expired - Fee Related
- 2000-09-29 US US09/676,972 patent/US6476038B1/en not_active Expired - Fee Related
- 2000-09-29 DE DE60032249T patent/DE60032249T2/de not_active Expired - Fee Related
- 2000-09-29 IL IL14890400A patent/IL148904A0/xx unknown
- 2000-09-29 EA EA200200421A patent/EA200200421A1/ru unknown
- 2000-09-29 ES ES00967132T patent/ES2277855T3/es not_active Expired - Lifetime
- 2000-09-29 YU YU23602A patent/YU23602A/sh unknown
- 2000-09-29 JP JP2001526540A patent/JP2003510326A/ja not_active Ceased
- 2000-09-29 WO PCT/US2000/026885 patent/WO2001023388A2/fr not_active Ceased
- 2000-09-29 AT AT00967132T patent/ATE347553T1/de not_active IP Right Cessation
- 2000-09-29 OA OA1200200088A patent/OA12049A/en unknown
- 2000-09-29 AU AU77379/00A patent/AU7737900A/en not_active Abandoned
- 2000-09-29 HU HU0203131A patent/HUP0203131A3/hu unknown
- 2000-09-29 PL PL00354982A patent/PL354982A1/xx not_active Application Discontinuation
- 2000-09-29 CZ CZ20021089A patent/CZ20021089A3/cs unknown
- 2000-09-29 EP EP00967132A patent/EP1218381B1/fr not_active Expired - Lifetime
- 2000-09-29 CN CN00813627A patent/CN1377355A/zh active Pending
2002
- 2002-03-11 BG BG106507A patent/BG106507A/xx unknown
- 2002-03-19 NO NO20021357A patent/NO20021357L/no not_active Application Discontinuation
- 2002-03-28 ZA ZA200202517A patent/ZA200202517B/xx unknown
2006
- 2006-09-06 JP JP2006241067A patent/JP2007077144A/ja active Pending

Also Published As

Publication number	Publication date
EP1218381B1 (fr)	2006-12-06
EA200200421A1 (ru)	2002-10-31
ZA200202517B (en)	2003-05-28
CA2379633A1 (fr)	2001-04-05
CZ20021089A3 (cs)	2002-11-13
WO2001023388A3 (fr)	2001-10-18
JP2003510326A (ja)	2003-03-18
DE60032249D1 (de)	2007-01-18
IL148904A0 (en)	2002-09-12
HUP0203131A2 (hu)	2003-01-28
HUP0203131A3 (en)	2004-06-28
YU23602A (sh)	2004-09-03
ES2277855T3 (es)	2007-08-01
AU7737900A (en)	2001-04-30
CN1377355A (zh)	2002-10-30
NO20021357L (no)	2002-05-23
PL354982A1 (en)	2004-03-22
JP2007077144A (ja)	2007-03-29
CA2379633C (fr)	2006-06-20
EP1218381A2 (fr)	2002-07-03
WO2001023388A2 (fr)	2001-04-05
DE60032249T2 (de)	2007-07-19
NO20021357D0 (no)	2002-03-19
ATE347553T1 (de)	2006-12-15
OA12049A (en)	2006-05-02
KR20020047201A (ko)	2002-06-21
US6476038B1 (en)	2002-11-05

Publication	Publication Date	Title
BG106507A (en)	2002-12-29	AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
BG106506A (en)	2002-12-29	ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a)-1,5-PYRIMIDINES AND PARAZOLO[1,5-a)-1,3,5-TRIAZINES
TR199801594A2 (xx)	1999-03-22	CCR-3 resept�r antagonistleri.
HUP0303651A3 (en)	2004-08-30	N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor and pharmaceutical compositions containing them
PL370972A1 (en)	2005-06-13	1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
MX9702307A (es)	1998-04-30	Pirrolo (2,3-d)pirimidinas y su uso.
MY118163A (en)	2004-09-30	Aryl fused azapolycyclic compounds
JO2359B1 (en)	2006-12-12	Benzathene derivatives as agents for modulation of GABA A receptor
IL141997A0 (en)	2002-03-10	Novel n-(iminomethyl) amine derivatives, their preparation, their use as medicines and compositions containing them
IL114599A0 (en)	1995-11-27	Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them
MY122278A (en)	2006-04-29	1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
BG108427A (en)	2005-01-31	2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulators
WO2002012224A3 (fr)	2002-07-18	Composes bicycliques
IL147149A0 (en)	2002-08-14	Novel diphenyl-piperidine derivate
AU4038600A (en)	2000-10-16	4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
AU1667500A (en)	2000-06-26	N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
HUP0301228A3 (en)	2005-08-29	3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity, process for their preparation and pharmaceutical compositions containing them
PL337221A1 (en)	2000-08-14	Carboxamides as antagonists of 5-ht1f
IL145645A0 (en)	2002-06-30	N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MXPA04000358A (es)	2004-05-04	Hexahidroazepino (4,5-g) indoles e indolinas como ligandos del receptor 5-ht.
WO2001068614A3 (fr)	2002-06-06	Arylpyrimidines substituees en position 5
AU3476599A (en)	1999-10-25	Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
SI1379239T1 (sl)	2008-02-29	N-(2-ariletil)benzilamini, uporabljeni kot antagonisti receptorja 5-ht6
WO2001046176A3 (fr)	2002-07-04	Antagonistes de recepteur de tachykinine non peptidique
PL370114A1 (en)	2005-05-16	Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists